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Abstract: Assessing the presence of ultrasonographic findings of Giant-Cell Arteritis 
in Polymyalgia Rheumatica patients using Ultrasonography on the temporal artery. 
The study contributes to the literature evaluating the unclear relationship between 
Polymyalgia Rheumatica and Giant-Cell Arteritis. It raises awareness that 
Ultrasonography can be used instead of biopsy in patients with suspected Giant-Cell 
Arteritis. Twenty patients were newly diagnosed with Polymyalgia Rheumatica, and 20 
participants as a control group were included in the study. While the Polymyalgia 
Rheumatica group was evaluated at baseline and sixth month, the control group was 
evaluated only at baseline. Laboratory, clinical and ultrasonographic findings of all 
participants were assessed. Gray-scale Ultrasonography and colored Doppler 
Ultrasonography were used to present halo and compression, occlusion, and stenosis 
in addition to intima-media complex thickness in bilateral temporal arteries and frontal-
parietal branches by an experienced radiologist blinded to the subject. No significant 
difference was found between Polymyalgia Rheumatica and control groups based on 
demographic features, clinical and ultrasonographic results at baseline and sixth 
month. Erythrocyte sedimentation rate of Polymyalgia Rheumatica at baseline was 
statistically higher than the control group. Erythrocyte sedimentation rate values have 
declined significantly in Polymyalgia Rheumatica patients, but no significant changes 
were found for clinical or ultrasonographic features during the sixth month. 
Ultrasonographic findings of Giant-Cell Arteritis are not present in newly diagnosed 
and six months followed up Polymyalgia Rheumatica patients. Further studies are 
needed. 
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INTRODUCTION 
Polymyalgia Rheumatica (PMR) is an inflammatory disease that affects elderly 
patients and is characterized by morning stiffness and pain in the shoulder and pelvic 
area. Although the disease's exact etiology is unclear, it is thought to be based on 
genetic and environmental factors. There is no clearly defined test for diagnosis, and 
the diagnosis is made by using clinical findings and lab testing, and imaging methods. 
Low-to-moderate dosage corticosteroid (CS) usage is the first treatment line in those 
cases (Yağcı İ., 2012).  
Giant-cell arteritis (GCA) is a systemic vasculitis that affects mid-to-large 
arteries and is also seen more frequently in elderly patients. A newly present headache 
in an elderly patient with rheumatic complaints might raise a GCA suspicion. In 
addition to headache, claudication of the jaw, problems with vision, and scalp 
sensitivity are also seen. Ultrasonography (US) and other imaging methods, in addition 
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to lab tests and even temporal artery biopsy in some cases, are used for differential 
diagnosis (Ulusoy H. et al., 2009). Temporal artery biopsy is not preferred due to its 
invasive nature and its relation with higher complication rates. The US is also told to 
be more cost-effective and has a higher sensitivity and specificity rate in GCA as artery 
biopsies only assess a specific area on a single artery (Schmidt, W.A., 2018). The 
treatment of choice in this condition is high-dosage corticosteroids (Ulusoy H. et al., 
2009). 
PMR and GCA are thought to be two severe diseases with a close relationship 
with each other. It is still unclear whether PMR and GCA are two different clinical 
manifestations of the same disease or just a partial overlap in clinical manifestation. 
PMR symptoms can begin before, during, or simultaneously with GCA symptoms. A 
review published in 2016 reported that 40 – 60% of GCA patients also showed PMR 
signs, and about 16 – 21% of PMR patients showed GCA symptoms (Buttgereit F. et 
al., 2016). GCA usually affects temporal arteries. In patients with PMR, temporal artery 
biopsies might show GCA findings, yet this is an invasive intervention related to high 
complication rates (Nesher G., 2008). Alternatively, subclinical GCA is reported to be 
diagnosable using vascular imaging methods in patients with isolated PMR diagnosis; 
however, it is rarely done, as reported by Dejaco C et al.’s study (Dejaco C. et al., 
2017). There are no previous studies in the literature that assess ultrasonographic 
GCA findings on PMR patients' temporal arteries. For this reason, following the 
recommendations previously mentioned in the literature (Schmidt W.A., 2018), we 
would like to evaluate the possibility of determining any ultrasonographic GCA findings 
on temporal arteries in PMR patients by supporting clinical and laboratory findings. 
 
MATERIALS AND METHOD 
Patients and Image Review 
 Thirty patients who were newly diagnosed with PMR using EULAR/ACR 
Provisional Classification Criteria for PMR (Dasgupta B. et al., 2012) were examined, 
and 20 patients were included in the study. Besides, 20 participants without PMR were 
included in the study as a control group between June 2019 - February 2020. Patients' 
demographics, systemic diseases, tobacco use, current medication usage, and GCA 
clinical manifestations were reviewed in detail. In GCA assessment, the jaw's 
presence of claudication, headache in the temporal region, vision problems, sensitivity 
and enlargement of temporal arteries, decreased or unfelt temporal artery pulse, and 
temporal artery murmur presence were all reviewed in the initial diagnosis and during 
the follow-up period. Patients with uncontrolled hypertension (4 patients), uncontrolled 
diabetes mellitus (2 patients), coronary disease (2 patients), and patients who smoke 
tobacco (2 patients) were excluded from the study by evaluating patient expressions 
and patient information on the automation system. Patients who did not use drugs 
regularly and did not go to regular physician control were defined as uncontrolled 
hypertension and uncontrolled diabetes mellitus. Patients were evaluated twice, at 
baseline and sixth month. While the PMR group was evaluated twice, the control group 
was evaluated only once. Clinical, laboratory, and ultrasonographic findings of all 
participants were assessed.  
 Informed consent was taken from all participating patients, and ethical approval 
for the study was obtained from the ethics committee of Giresun University (90139838-




Medical Laboratory Technology Journal |  
 
Copyright © 2021, MLTJ, ISSN 2461-0879 
 
Ultrasonographic Evaluation 
All patients were assessed by an experienced radiologist with 15 years of 
experience and were blinded to their previous clinical status. The radiological 
assessment was done using gray-scale US and color Doppler US on temporal arteries 
of the patients. Toshiba Aplio 500 US device (Toshiba Medical System Corporation, 
Tokyo, Japan), armed with a high-frequency linear probe that supports Doppler mode 
usage (PLT-1005 BT [4-14 MHz]) was used for the US. Doppler frequency was set at 
10 MHz, Pulse Repetition Frequency (PRF) 2-3 kHz, focus setting 5 mm, and depth 
setting as 1-2 cm. Common superficial, temporary arteries, frontal, and parietal 
branches are bilaterally reviewed on longitudinal and axial planes. The presence of 
halo sign, compression sign, occlusion, and stenosis, characteristic of GCA, was 
reviewed (Schmidt W.A., 2018). Also, intima-media complex measurement, which is 
known to give higher values in vasculitis, was done using Schäfer VS et al.’s study as 
reference (Schäfer VS. et al., 2017). Halo sign diameter cut-off value was set at 0.42 
mm for typical superficial, temporary artery, 0.34 mm for frontal branch, and 0.29 mm 
for the parietal branch. Intima-media thickness cut-off value was set as 0.2 mm 
(Schäfer VS. et al., 2017), and mean values of bilateral temporal arteries were 
accepted. "Compression sign" was defined as artery not compressed when the US 
probe applied pressure. "Occlusion" was defined as a temporal artery filled with 
hypoechoic material despite PRF decrease and increased color enrichment setting 
and cannot show Doppler signal. Finally, "stenosis" was defined as turbulent colored 
pattern presence and persistent diastolic refill in pressure-wavy doppler US with 
increased maximum systolic flow intensity recorded as "positive" or "negative" 
(Schmidt W.A., 2018).  
Statistical Analysis 
 The SPPS package program has analyzed the data for this research. 
Descriptive statistics have been given as averages ± standard deviations and numbers 
(percent). For the comparison of independent categorical variables, Fisher's exact test 
is used, while McNemar’s test analyzes dependent categorical variables. Normality 
analysis has been conducted by graphical (histogram and probability distributions) and 
analytical (Shapiro-Wilk test) methods. Since all the data showed normal distribution, 
the Student t-test was used to compare independent groups, while the paired sample 
t-test was used to compare dependent groups. Statistical significance level has been 
accepted as p<0,05. 
 
RESULTS AND DISCUSSION 
Our study had 40 participants in total. Twenty of them were PMR patients, while 
the other 20 subjects were used as the control group. The average age of the 
participants was 69,18±9,45. Researchers had 32 females (80%) and eight males 
(20%). When the researcher compared the PMR group and the control group, no 
statistically significant differences were found based on their demographic features 
(age, gender, BMI) and their ultrasonographic results. However, when we compared 
them based on their clinical features and ESR values, we did find that the erythrocyte 
sedimentation rate of PMR patients was statistically higher than the control group 
(p<0,001). 
Our study had 40 participants in total. Twenty of them were PMR patients, while 
the other 20 subjects were used as the control group. The average age of the 
participants was 69,18±9,45. Researchers had 32 females (80%) and eight males 
(20%). When the researcher compared the PMR group and the control group, no 
statistically significant differences were found based on their demographic features 
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(age, gender, BMI) and their ultrasonographic results. However, when we compared 
them based on their clinical features and ESR values, we did find that the erythrocyte 
sedimentation rate of PMR patients was statistically higher than the control group 
(p<0,001). 
PMR: Polymyalgia Rheumatica, TA: Temporal artery ESR: Erythrocyte 
sedimentation rate 
 
PMR: Polymyalgia rheumatica, BMI: Body mass index, TA: Temporal artery, 
ESR: Erythrocyte sedimentation rate 
 
Table 1. Comparison of Demographic Features, Clinical Features, ESR, and 
Ultrasonographic Findings of the PMR Group at Baseline and Control Group 
 






Demographic Features    
Age, Years  70,65±10,99 67,70±7,62 0,330 
Gender, Female/Male 17 (85,0)/3 (15,0) 15 (75,0)/5 (25,0) 0,695 
BMI, kg/m² 30,41±4,07 29,77±2,71 0,565 
Clinical Features    
Jaw Claudication, n(%) 3 (15,0) 1 (5,0) 0,605 
Scalp Tenderness,   n(%) 3 (15,0) 2 (10,0) 1,000 
New Onset Headache,  n(%) 4 (20,0) 2 (10,0) 0,661 
Vision Problems,  n(%) 1 (5,0) 1 (5,0) 1.000 
ESR, mm/h 78,05±18,48 28,20±12,13 <0,001 
Ultrasonographic Findings    
Intima-media Thickness of 
TA, mm 
0,153±0,028 0,147±0,020 0,480 
Halo Sign 0 0  
Compression Sign 0 0  
Stenosis 0 0  
Occlusion  0 0  
Table 2. Comparison of Clinical Features, ESR, and Ultrasonographic Findings of 
the PMR Group at the Sixth Month and Control Group 
 





Jaw Claudication, n(%) 2 (10,0) 1 (5,0) 1,000 
Scalp Tenderness, n(%) 3 (15,0) 2 (10,0) 1,000 
New Onset Headache, n(%)  2 (10,0) 2 (10,0) 1,000 
Vision Problems, n(%)  0 (0,0) 1 (5,0) 1.000 
ESR, mm/h 30,40±16,08 28,20±12,13 0,628 
Ultrasonographic Findings    
Intima-media Thickness of TA, mm 0,154±0,021 0,147±0,020 0,315 
Halo sign, n(%) 0 0  
Compression Sign, n(%) 0 0  
Stenosis, n(%) 0 0  
Occlusion , n(%) 0 0  
Medical Laboratory Technology Journal |  
 
Copyright © 2021, MLTJ, ISSN 2461-0879 
 
PMR: Polymyalgia rheumatica, ESR: Erythrocyte sedimentation rate, TA: Temporal 
artery 
 
In contrast, we did not find any statistically significant differences between 
groups based on jaw claudication, scalp tenderness, new-onset headache, and vision 
problems (Table 1). On the other hand, no significant differences were found between 
the PMR group in the sixth month and the control group based on their clinical features 
and ultrasonographic results (Table 2). Lastly, when we compared the clinical features, 
ESR, and ultrasonographic results of the PMR group at baseline and sixth month, we 
found that the ESR decreased statistically significantly at the 6th month according to 
the basal evaluation in the PMR group. In contrast, no statistically significant changes 
were found between groups for other clinical features (Table 3). Ultrasonographic 
results did not show any halo sign, compression sign, stenosis, and occlusion findings 
for the PMR group at baseline and sixth month. 
 Although previous studies in the literature reported GCA diagnosed in about 16-
21% of PMR patients (Buttgereit F. et al., 2016), our study did not show any 
ultrasonographic or significant clinical GCA signs in any of our patients at baseline and 
sixth month. This means attributed to the fact that although an experienced radiologist 
did the assessment, the assessment was done using the US, which is a reliable 
method that was extensively researched yet is still debated as a form of a concrete 
diagnostic tool in GCA. Researchers did not perform a temporal artery biopsy in any 
of our patients, which is the most powerful GCA diagnosis method. This is backed up 
by the previous studies in the literature, which report that GCA signs can be seen in 
patients with PMR in temporal artery biopsy (Nesher G., 2008). Another reason is the 
Table 3.  Comparison of Clinical Features, ESR, and Ultrasonographic Findings of the 
PMR Group at Baseline and Sixth Month 
  
  P-value 
Jaw Claudication at the Sixth Month 1,000 
Jaw Claudication at Baseline  Yes No  
Yes 2 1  
No 0 17  
 Scalp Tenderness at the Sixth Month 1,000 
Scalp Tenderness at Baseline Yes No  
Yes 2 1  
No 1 16  
 New-onset Headache During the Sixth 
Month 
0,500 
New-onset Headache at Baseline Yes No  
Yes 2 1  
No 1 16  
 Vision Problems During the Sixth Month 1,000 
Vision Problems at Baseline Yes No  
Yes 2 1  
No 1 16  
 PMR at 
baseline 
PMR at the sixth 
month 
 
ESR, mm/h 78,05±18,48 30,40±16,08 <0,001 
Intima-media Thickness of TA, mm 0,153±0,028 0,154±0,021 0,748 
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relatively short follow-up period, which is six months for the study. The possibility of 
those patients developing GCA in the late-term will be reviewed in our routine follow-
up. Finally, although patients were evaluated before CS usage, CS might have 
affected ultrasonographic imaging results in the 6th month despite low dosages.  
 PMR and GCA's relationship has been debated within the medical community 
without a clear consensus. It was previously determined that those two were different 
conditions even though sharing some common points, such as starting at an advanced 
age, seen more frequently in females, showing a systematic inflammatory response 
and adequate reaction to CS treatment (Gonzalez-Gay MA., 2004). As opposed to this 
study, GCA was defined as a vasculitis syndrome, including large artery vasculitis and 
PMR, in a study done in 2016 (Dejaco C. et al., 2016). Some authors argue that PMR 
is a mild form of GCA. A review done in 2016 reported that about 40-60 % of GCA 
patients showed PMR findings at baseline, and 16-21% of PMR patients showed GCA 
symptoms (Buttgereit F. et al., 2016). Dejaco C. et al.’s study (Dejaco C. et al., 2017) 
reported that subclinical GCA can be diagnosed using vascular imaging methods in 
patients with isolated PMR diagnosis yet was seldom performed.  
 Additional difficulties in diagnosis include the absence of a specific lab test in 
both conditions and the fact that even temporal artery biopsy, which is deemed as the 
gold standard in diagnosis, show a positive outcome in 39-87%, with even <60% of 
dominant large artery GCA patients (Brack A. et al., 1999; Diamantopoulos AP. et al., 
2014; Roth AM. et al.., 1984; Hall S. et al., 1983; Luqmani R. et al., 2016). 
 Although GCA and PMR-specific imagining techniques show a rapid 
progression, there is still no explicit agreement on when to use which technique. US 
is deemed as the primary imaging method in GCA and PMR diagnosis. Although 
previous critical studies reported halo sign sensitivity as 55-100% and specificity as 
78-100% in the US, this imaging method still did not replace temporal artery biopsy in 
GCA diagnosis (Dejaco C. et al., 2017). Tabul study (Luqmani R. et al., 2016), which 
prospectively compared temporal artery biopsy and color doppler US, reported 
sensitivity as 39% to 54% and specificity as 100% to 81%, respectively. There are no 
previous studies in the literature that assess temporal artery using US to detect GCA 
findings in PMR patients. However, a similar study done by Gonzales S et al. 
(González SP. et al., 2018) reported 22 positive US results in 53 patients with 
suspected GCA and diagnosed 8 of those with GCA, 4 of them with PMR. However, 
in that study, the patients were deemed "GCA suspected," whereas in our study, 
despite some patients having doubtful GCA symptoms, none of them had GCA 
suspicion. GCA shows four characteristic pathologies in the US: the thickening of the 
arterial wall (halo sign), inability to compress artery (compression), stenosis, and 
occlusion.  In GCA, cellular infiltrates, and edema can build up in intima and spread to 
media and adventitia surfaces.  
 This thickening shows a hypoechoic image around the US's artery and is 
defined as a "halo sign" (Schmidt WA., 1995). The previous studies defined cut-off 
values for halo sign diameter as 0.3 – 1 mm (Schmidt, W.A., 2018). Another recent 
study reported normal intima-media complex diameter as around 0.2 mm and can 
increase to 0.5-0.8 mm in vasculitis (Schäfer VS. et al., 2017). A key point in the 
assessment is the experience requirement in this field as the previous studies reported 
incompetence in most of the clinicians who perform US in this field (Dasgupta B. et 
al., 2012). Our study's radiological assessment was done by a radiologist who has 
remarkable experience in the temporal artery in the US to circumvent this risk. 
Although the idea that subclinical GCA diagnosis might be possible using vascular 
imaging methods in isolated PMR cases was voiced in previous studies (Dejaco C. et 
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al., 2017), we could not detect any GCA findings when temporal arteries were 
reviewed using gray-scale and color doppler US.  
Previous studies showed that the halo sign on GCA's temporal artery could 
disappear in 2 weeks with high-dosage CS treatment reappearing only on major 
relapses (Karahaliou M. et al., 2006; Habib HM. et al., 2012; De Miguel E. et al., 2012). 
GCA CS dosages used in the treatment are much higher than PMR dosages. The 
literature reports that relapses can be seen even in such high doses, and halo sign 
which disappeared with treatment might show up again. In our study, patients were 
evaluated at baseline before CS usage to prevent possible effects of CS, and no halo 
sign was detected. After the first evaluation, all patients administered low-dosage CS, 
and a halo sign was not detected in any of the patients on the 6th month. The fact that 
researchers were unable to clearly distinguish the reason if this is due to CS usage or 
that there is no halo sign which might point to a subclinical GCA in the first place can 
be considered as a limitation of our study. However, as mentioned above, PMR 
patients can develop GCA even under CS treatments. Therefore, using corticosteroids 
in lower dosages and the fact that PMR patients might develop GCA even under CS 
treatment leads us to think that the reason for not seeing halo sign in the US due to 
CS usage is unlikely. Our study's other limitations are the low number of patients and 
the limited follow-up period of 6 months. 
 
CONCLUSION 
 Ultrasonographic findings of GCA are not present in newly diagnosed and six 
months followed up PMR patients. However, we recommend that the temporal arter 
US be an alternative to temporal arter biopsy as a non-invasive and effective method 
in patients with clinical GCA suspicion. Researchers recommend that additional 
studies are necessary to evaluate this subject further. 
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